Financial Report: Bristol-Myers Squibb 3Q

Bristol-Myers Squibb 3Q

3Q Revenues: $4.8 billion (flat)

3Q Earnings: $949 million (-2%)

YTD Revenues: $14.4 billion (+4%)

YTD Earnings: $2.6 billion (+1%)

Comments: Plavix sales were up 7% to $1.7 billion, but Abilify sales were -7% to $608 million, resulting from changed rebate rates. Baraclude sales were up 19% to $228 million. Sustiva sales were up 9% to $342 million and Reyataz rose 4% to $375 million. Sprycel sales were $144 million (+35%) and Orencia sales were $184 million (+14%). Avapro/Avalide sales were down 8% to $303 million and Erbitux sales dropped 11% to $159 million. U.S. health care reform had a 2% negative effect on sales in the quarter. R&D expenses were flat at $824 million in the quarter.